Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.7989 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.4951 | 0.5346 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0435 | 0.0545 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.7989 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4087 | 0.4413 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 0.9213 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4951 | 0.6197 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0618 | 0.0667 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.7989 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4951 | 0.6197 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.566 | 0.4979 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.7989 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4951 | 0.6197 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0618 | 0.0773 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4951 | 0.6197 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3679 | 0.3972 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.7989 | 0.8626 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7978 | 0.9986 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.7989 | 1 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0435 | 0.0545 |
Brugia malayi | RNA binding protein | 0.0076 | 0.7989 | 0.7673 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.7989 | 0.8626 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 0.9213 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4078 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.7989 | 0.7673 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0947 | 0.1186 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0947 | 0.1186 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4951 | 0.6197 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0106 | 0.0114 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.2938 | 0.183 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.7989 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.7989 | 0.7673 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.566 | 0.6111 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.2938 | 0.3172 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9262 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.4951 | 0.4159 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.566 | 0.4979 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4951 | 0.6197 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4417 | 0.4769 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.2938 | 0.3678 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.566 | 0.6111 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4078 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.7989 | 1 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0947 | 0.1186 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3667 | 0.2673 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.7989 | 0.8626 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0435 | 0.0545 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4951 | 0.6197 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.5012 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | = 5.6234 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.5113 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of Trypanosoma Brucei Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.